Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025)
Candel Therapeutics recorded quarterly Non-Current Deffered Revenue of $89000.0 in Q4 2025, down 17.59% quarter-over-quarter from $108000.0 in Q3 2023.
Candel Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $89000.0 for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $89000.0; the TTM figure through Dec 2025 stood at $89000.0 (changed N/A YoY), while the FY2025 annual figure was $89000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $89000.0 for Q4 2025 at Candel Therapeutics, down from $108000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $894000.0 in Q4 2021 to a low of $31000.0 in Q3 2021.
- A 4-year average of $262375.0 and a median of $126000.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue jumped 615.2% in 2021 and plunged 83.89% in 2022, its largest moves.
- Candel Therapeutics' Non-Current Deffered Revenue stood at $894000.0 in 2021, then slumped by 83.89% to $144000.0 in 2022, then fell by 25.0% to $108000.0 in 2023, then retreated by 17.59% to $89000.0 in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $89000.0, $108000.0, and $120000.0 for Q4 2025, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2023 | 108,000.00 |
| Jun 30, 2023 | 120,000.00 |
| Mar 31, 2023 | 132,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Dec 31, 2021 | 894,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 581,000.00 |
| Dec 31, 2020 | 125,000.00 |